{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:45:43Z","timestamp":1761554743611,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.hfc.2021.01.006","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:36:05Z","timestamp":1613036165000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novelties in Therapy of Chronic Heart Failure"],"prefix":"10.1016","volume":"17","author":[{"given":"Sara","family":"Doimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2021.01.006_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.hfc.2021.01.006_bib2","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2021.01.006_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2021.01.006_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10741-019-09879-x","article-title":"Angiotensin receptor\/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings","volume":"25","author":"Ksi\u0105\u017cczyk","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.hfc.2021.01.006_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hfc.2021.01.006_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hfc.2021.01.006_bib11","doi-asserted-by":"crossref","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00125-016-4172-4","article-title":"Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels","volume":"60","author":"Willard","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.hfc.2021.01.006_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2021.01.006_bib14","doi-asserted-by":"crossref","first-page":"e003430","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hfc.2021.01.006_bib16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2021.01.006_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2021.01.006_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib20","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0735-1097(03)00947-1","article-title":"Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure","volume":"42","author":"Braunstein","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.01.006_bib21","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2021.01.006_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2018.05.016","article-title":"Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)","volume":"203","author":"Arnold","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2021.01.006_bib23","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.hfc.2021.01.006_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.006_bib25","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1002\/ehf2.12891","article-title":"Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME","volume":"7","author":"Pellicori","year":"2020","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib28","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hfc.2021.01.006_bib29","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib30","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2021.01.006_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 2","key":"10.1016\/j.hfc.2021.01.006_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dom.13678","article-title":"Effects of sodium glucose cotransporter type 2 inhibitors on heart failure","volume":"21","author":"Nassif","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.hfc.2021.01.006_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.01.006_bib35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2459\/JCM.0000000000000850","article-title":"New drugs for the treatment of chronic heart failure with a reduced ejection fraction: what the future may hold","volume":"20","author":"Sciatti","year":"2019","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.hfc.2021.01.006_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca.11.71","article-title":"PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016","volume":"8","author":"Buysse","year":"2012","journal-title":"Future Cardiol"},{"key":"10.1016\/j.hfc.2021.01.006_bib37","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.hfc.2021.01.006_bib38","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib39","doi-asserted-by":"crossref","first-page":"e006817","DOI":"10.1161\/JAHA.117.006817","article-title":"Role of volume redistribution in the congestion of heart failure","volume":"6","author":"Fudim","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.hfc.2021.01.006_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1152\/japplphysiol.00069.2017","article-title":"Raising the pressure: hemodynamic effects of splanchnic nerve stimulation","volume":"123","author":"Fudim","year":"2017","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.hfc.2021.01.006_bib41","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.118.035260","article-title":"Splanchnic nerve block for acute heart failure","volume":"138","author":"Fudim","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2021.01.006_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jchf.2020.04.010","article-title":"Splanchnic nerve block for chronic heart failure","volume":"8","author":"Fudim","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib43","doi-asserted-by":"crossref","first-page":"e12709","DOI":"10.1097\/MD.0000000000012709","article-title":"The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hfc.2021.01.006_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA Trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ahj.2020.01.009","volume":"222","author":"Udelson","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2021.01.006_bib46","doi-asserted-by":"crossref","first-page":"e005998","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rationale and design of the VITALITY-HFpEF Trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.006_bib47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory cytokines and chemokines as therapeutic targets in heart failure","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hfc.2021.01.006_bib48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.01.006_bib49","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.01.006_bib50","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.01.006_bib51","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2021.01.006_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.006_bib53","article-title":"A\u00a0systematic review and meta-analysis: safety and efficacy of mesenchymal stem cells therapy for heart failure","author":"Shen","year":"2020","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.hfc.2021.01.006_bib54","first-page":"CD007888","article-title":"Stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"12","author":"Fisher","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:41:08Z","timestamp":1761554468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713621000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1551713621000064"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2021.01.006","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novelties in Therapy of Chronic Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2021.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}